treatment delays are also causing needless anxiety and distress to patients as well as putting lives at serious risk.
.
.
yet these drugs are not a "home run," says elizabeth loder, md, a professor of neurology at harvard medical school and chief of the division of headache at brigham & women's hospital.
.
services
.: "arise: a phase 3 randomized trial of erenumab for episodic migraine."
.
.